• FDA grants Orphan Drug Designation for eftilagimod alfa (efti) in Soft Tissue Sarcoma
• Efti demonstrated promising results in Phase II EFTISARC-NEO trial, meeting primary endpoint
• Designation recognizes efti's potential therapeutic relevance in this rare cancer

Immutep Limited, a clinical-stage biotechnology company, has announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for eftilagimod alfa ('efti') for the treatment of Soft Tissue Sarcoma (STS), a rare cancer with significant unmet medical need. The FDA's Orphan Drug Designation program is designed to encourage development of therapies for rare diseases affecting fewer than 200,000 people in the United States. Benefits of ODD may include regulatory support, potential tax credits, fee exemptions, and seven years of market exclusivity upon approval. This designation recognises the potential therapeutic relevance of efti in STS, supported by encouraging clinical data from the investigator-initiated Phase II EFTISARC-NEO trial which has been evaluating efti in combination with radiotherapy and KEYTRUDA® (pembrolizumab) in the neoadjuvant setting in patients with resectable soft tissue sarcoma. In 38 evaluable patients, the study met its primary endpoint, demonstrating a median tumour hyalinization/fibrosis of 51.5%, significantly exceeding the pre-specified target of 35% and historical benchmarks of ~15% with radiotherapy alone. These results were observed across multiple sarcoma subtypes and were supported by translational data showing immune activation consistent with efti's mechanism of action, with a favourable safety profile and no delays to planned surgery.

The FDA's designation, based on very encouraging data from the EFTISARC-NEO trial, provides Immutep with a potential direct step forward into a late-stage study in the neoadjuvant setting for Soft Tissue Sarcoma.